$2.08
-0.12 (-5.45%)
Open$2.35
Previous Close$2.20
Day High$2.50
Day Low$1.77
52W High$9.50
52W Low$1.71
Volume—
Avg Volume56.4K
Market Cap16.06M
P/E Ratio—
EPS$-1.54
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,381.7% upside
Current
$2.08
$2.08
Target
$30.82
$30.82
$21.30
$30.82 avg
$34.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.77M | 10.40M | 9.97M |
| Net Income | -34,356,212 | 1.68M | 1.79M |
| Profit Margin | -1,940.2% | 16.1% | 17.9% |
| EBITDA | -34,210,763 | 3.32M | 3.17M |
| Free Cash Flow | — | 838.7K | 1.16M |
| Rev Growth | — | +2.0% | -1.5% |
| Debt/Equity | — | 0.33 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |